Efficacy and Safety of Anti-Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab in Neonates: A Real-World Monocentric Study.

Vaccines (Basel) · 2025 · PMC12390192 · PMID 40872923

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

slightly significantp = 0.051so close (0.05 < p ≤ 0.1)

This reduction was slightly significant when compared to the 2023–2024 season (Mid-P exact test, p = 0.051), with a corresponding risk ratio of 0.31 for 2024–2025 vs. 2023–2024 (95%CI, 0.09–1.13) and a 69% reduction ( Table 2 ).

also in 1,762 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.